Loading…
Chinese maker of medical diagnostic ultrasound systems and industrial ultrasonic non-destructive testing instruments.
Chinese maker of medical diagnostic ultrasound systems and industrial ultrasonic non-destructive testing instruments.
Sells ultrasound systems and flaw detectors by unit, so orders follow hospital equipment budgets and industrial maintenance spending. The medical and industrial lines serve different buyers but rely on the same ultrasound know-how.
In one line: A Chinese Mindray/Olympus hybrid spanning medical and industrial ultrasound.
Moat: narrow (brand, installed base). Long-established SIUI brand across both medical and industrial ultrasound markets.
Headquarters: Shantou, Guangdong, China · Employees: 737
Size Shantou Institute of Ultrasonic Instruments (301602.SZ) is a China Health Care company (Medical Specialties) with a market value of $944M, the 2417th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥14.69 on 6 Nov 2026.
Performance Over six months the shares fell 19.2%, against -16.6% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 3.8% over the last twelve months (peer median +5.4%); the operating margin is 30.2% (peer median 9.0%).
Valuation It trades at 13.5× enterprise value to sales against a peer median of 3.4× (2nd most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 40.7 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥382M | CN¥403M | CN¥372M | CN¥323M | CN¥336M |
| Revenue growth | — | +8% | +15% | -4% | — |
| Gross profit | CN¥261M | CN¥280M | CN¥254M | CN¥214M | n/a |
| EBITDA | n/a | CN¥157M | CN¥144M | CN¥113M | n/a |
| Net income | CN¥103M | CN¥149M | CN¥146M | CN¥115M | CN¥127M |
| Free cash flow | CN¥140M | CN¥133M | CN¥126M | CN¥87.7M | n/a |
| Capital expenditure | CN¥21.5M | CN¥15.2M | CN¥18.7M | CN¥1.53M | n/a |
| Total debt | CN¥0 | CN¥7.04M | CN¥7.03M | CN¥7.02M | n/a |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Shantou Institute of Ultrasonic Instruments 301602.SZ | $944M | -19% | +4% | 30% | 13.5× | 13.1% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.4B | +9% | +5% | 28% | 6.1× | 0.9% |
| Olympus 7733.T | $12.2B | +13% | +8% | 16% | 2.0× | -1.5% |
| GE HealthCare GEHC | $37.2B | +30% | +7% | 14% | 2.1× | 4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301602.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | -4.8% | 8th lowest of 21 |
| 6-month return | -19.2% | -16.6% | 10th lowest of 21 |
| Distance from 52-week high | -42.7% | -37.3% | 10th lowest of 21 |
| Revenue growth (TTM) | +3.8% | +5.4% | 9th lowest of 21 |
| Operating margin | 30.2% | 9.0% | highest of 21 |
| EV / Sales | 13.5× | 3.4× | 2nd most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 13.1% | 7.1% | 7th most demanding of 15 |
| Growth delivered (Del g) | +4.6% | +12.1% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | +8.4 pp | -4.2 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | +40.7 pp | +1.5 pp | highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | 13.5× | 13.1% | +4.6% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 3.4× | 3.1% | +12.7% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 10.3× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 5.6× | n/a | n/a |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | 11.7× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 2.5× | 7.2% | +12.1% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 8.0× | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 4.2× | 19.9% | +23.3% |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 15.6× | 40.1% | +12.4% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 1.6× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | 9.6× | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 4.0× | 13.3% | +15.5% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 3.5× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 1.9× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 3.5× | 1.5% | +13.9% |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 2.8× | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | 2.1× | n/a | n/a |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 2.0× | 6.9% | +12.1% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 0.8× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 0.8× | -12.9% | -1.3% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 1.7× | -7.0% | +11.3% |